Plasma and Serum Serotonin Levels and their Relationship to Orofacial Pain and Anxiety in Fibromyalgia

Journal of Orofacial Pain

Volumn 14, Issue 1, 2000, Pages 37-46

  Ernberg, Malin ^a   Voog, Ulle ^a,b   Alstergren, Per ^a   Lundeberg, Thomas ^a   Kopp, Sigvard ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF TARTU   (Estonia)

Author keywords

Anxiety; Fibromyalgia; Pain threshold; Serotonin; Visual analog pain scale

Indexed keywords

SEROTONIN;

ANXIETY; ARTICLE; BLOOD; CASE CONTROL STUDY; CLASSIFICATION; DAILY LIFE ACTIVITY; FACE MUSCLE; FACE PAIN; FEMALE; FIBROMYALGIA; HUMAN; MASSETER MUSCLE; METABOLISM; MIDDLE AGED; NOCICEPTIVE RECEPTOR; NONPARAMETRIC TEST; PAIN ASSESSMENT; PAIN THRESHOLD; PATHOPHYSIOLOGY; PHYSIOLOGY; PLASMA; PSYCHOLOGICAL ASPECT; RHEUMATOID ARTHRITIS; SECRETION; THROMBOCYTE;

ACTIVITIES OF DAILY LIVING; ANXIETY; ARTHRITIS, RHEUMATOID; BLOOD PLATELETS; CASE-CONTROL STUDIES; FACIAL MUSCLES; FACIAL PAIN; FEMALE; FIBROMYALGIA; HUMANS; MASSETER MUSCLE; MIDDLE AGED; NOCICEPTORS; PAIN MEASUREMENT; PAIN THRESHOLD; PLASMA; SEROTONIN; STATISTICS, NONPARAMETRIC;

EID: 0034569406     PISSN: 10646655     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Wolfe F, Russell IJ, Vipraio G, Ross K, Anderson J. Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population. J Rheumatol 1997; 24:555-559.
2. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-172.
3. Eriksson PO, Lindman R, Stål P, Bengtsson A. Symptoms and signs of mandibular dysfunction in primary fibromyalgia syndrome (PSF) patients. Swed Dent J 1988; 12:141-149.
4. Hedenberg-Magnusson B, Ernberg M, Kopp S. Symptoms and signs of temporomandibular disorders in patients with fibromyalgia and local myalgia of the temporomandibular system. A comparative study. Acta Odontol Scand 1997;6:344-349.
5. Moldofsky H, Warsh JJ. Plasma tryptophan and musculoskeletal pain in non-articular rheumatism ("fibrositis syndrome"). Pain 1978;5:65-71.
6. Yunus MB, Dailey JW, Aldag JC, Masi AT, Jobe PC. Plasma tryptophan and other aminu acids in primary fibromyalgia: A controlled study. J Rheumatol 1992;19:90-94.
7. Russell IJ, Vaerøy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35:550-556.
8. Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Javors MA, Bowden CA. Platelet 3h-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1992; 19:104-109.
9. Stratz T, Samborski W, Hrycaj P, Pap T, Mackiewicz S, Menuet P, Müller W. Serotonin concentration in serum of patients with generalized tendomyopathy (fibromyalgia) and chronic polyarthritis. Med Klin 1993;88:458-462.
10. Ernberg M, Hedenberg-Magnusson B, Alstergren P, Lundeberg T, Kopp S. Pain, allodynia and serum serotonin level in orofacial pain of muscular origin. J Orofac Pain 1999;13:56-62.
11. Moldofsky H. Rheumatic pain modulation syndrome: The interrelationships between sleep, central nervous system serotonin, and pain. Adv Neurol 1982;33:51-57.
12. Russell IJ, Vipraio GA, Morgan WW, Bowden CL. Is there a metabolic basis for the fibrositis syndrome? Am J Med 1986;81:50-54.
13. Krag NJ, Nørregaard J, Hindberg I, Larsen JK, Danneskiold-Samsae B. Psychopathology measured by established self-rating scales and correlated to serotonin measures in patients with fibromyalgia. Eur Psychiatry 1995)10:404-409.
14. Hindberg I, Naesh O. Serotonin concentrations in plasma and variations during the menstrual cycle. Clin Chem 1992)38:2087-2089.
15. Endresen GK. Evidence for activation of platelets in the synovial fluid from patients with rheumatoid arthritis. Rheumatol Int 1989;9:19-24.
16. Alstergren P, Kopp S. Pain and synovial fluid concentration of serotonin in arthritic temporomandibular joints. Pain 1997;72:137-143.
17. Herbert MK, Schmidt RF. Activation of normal and inflamed fine articular afferent units by serotonin. Pain 1992;50:79-88.
18. Hrycaj P, Stratz T, Mennet P, Müller W. Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome-A preliminary study. J Rheumatol 1996;23:1418-1423.
19. Taiwo YO, Levinc JD. 1 Serotonin is a directly-acting hyperalgesic agent in the rat. Neuroscience 1992; 48:485-490.
20. Ernberg M, Hedenberg-Magnusson B, Alstergren P, Kopp S. The level of serotonin in the superficial masseter muscle in relation to local pain and allodynia. Life Sci 1999;65:313-325.
21. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324.
22. Jensen MP, McFarland CA. Increasing the reliability and validity of pain intensity measurement in chronic pain patients. Pain 1993;55:195-203.
23. Margolis RB, Chibnall JT, Tait RC. Test-retest reliability of the pain drawing instrument. Pain 1988;33:49-51.
24. List T, Helkimo M. A scale for measuring the activities of daily living (ADL) of patients with craniomandibular disorders. Swed Dent J 1995;19:33-40.
25. Spielberger CD. The measurement of state and trait anxiety: Conceptual and methodological issues. In: Levi L (ed). Emotions: Their Parameters and Measurement. New York: Raven Press, 1975:713-725.
26. Forsberg C, Björvell H. Swedish population norms for the GHRI, HI and STAI-state. Qual Life Res 1993;2:349-356.
27. Candito M, Souetre E, Iordache A, Pringuey D, Ardisson JL, Chambon P, Darcourt G. Diurnal variation in total plasma tryptophan in controls and in depression. J Psychiatr Res 1990;24:227-230.
28. Fetkovska N, Amstein R, Ferracin F, Regenass M, Buhler FR, Pletscher A. 5HT-kinetics and sensitivity of human blood platelets: Variations with age, gender and platelet number. Thromb Haemost 1988;60:486-490.
29. Wolfe BE, Metzger ED, Stollar C. The effects of dieting on plasma tryptophan concentration and food intake in healthy women. Physiol Behav 1997;61:537-541.
30. Alvarez JC, Gluck N, Fallet A, Gregoire A, Chevalier JF, Advenier C, Spreux-Varoquaux O. Plasma serotonin level after 1 day of fluoxetine treatment: A biological predictor for antidepressant response? Psychopharmacology (Berl) 1999;143:97-101.
31. Kalra U, Chitkara N, Dadoo RC, Singh GP, Gulati P, Narula S. Evaluation of plasma serotonin concentration in acute appendicitis. Indian J Gastroenterol 1997;16:18-19.
32. Yunus MB. Towards a model of pathophysiology of fibromyalgia: Aberrant central pain mechanisms with peripheral modulation. J Rheumatol 1992;193:846-850.
33. Wolfe K, Cathey MA, Kleinheksel SM, Amos SP, Hoffman RG, Young DY, Hawley DJ. Psychological status in primary fibrositis and fibrositis associated with rheumatoid arthritis. J Rheumatol 1984;11:500-506.
34. Hudson JI, Goldenberg DL, Pope HG Jr, Keck PE Jr, Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 1992;92:363-367.
35. Krag NJ, Nørregaard J, Larsen JK, Danneskiold-Samsøe B. A blinded, controlled evaluation of anxiety and depressive symptoms in patients with fibromyalgia, as measured by standardized psychometric interview scales. Acta Psychiatr Scand 1994;89:370-375.
36. Glover V, Jarman J, Sandler M. Migraine and depression: Biological aspects. J Psychiatr Res 1993;27:223-231.
37. Juhl JH. Fibromyalgia and the serotonin pathway. Altern Med Rev 1998;3:367-375.
38. Magni G. On the relationship between chronic pain and depression when there is no organic lesion. Pain 1987;31:1-21.
39. Atkinson JH, Slater MA, Patterson TL, Grant I, Garfin SR. Prevalence, onset, and risk of psychiatric disorders in men with chronic low back pain: A controlled study. Pain 1991;45:111-121.
40. Widerström-Noga E, Dyrehag LE, Börglum-Jensen L, Åslund PC, Wenneberg B, Andersson SA. Pain threshold responses to two different modes of sensory stimulation in patients with orofacial muscular pain: Psychologic considerations. J Orofac Pain 1998;12:27-34.
41. 3 receptor antagonists of release of cholecystokinin-like immunoreactivity from the frontal cortex of freely moving rats. Naunyn Schmiedebergs Arch Pharmacol 1993;347:111-114.
42. Scudds RA, Trachsel LC, Luckhurst BJ, Percy JS. A comparative study of pain, sleep quality and pain responsiveness in fibrositis and myofascial pain syndrome. J Rheumatol Suppl 1989;19;120-126.
43. Kosek E, Ekholm J, Hansson P. Sensory dysfunction in fibromyalgia patients with implications for pathogenic mechanisms. Pain 1996;68:37.5-383.
44. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994;37:1593-1601.
45. Vaerøy H, Helle R, Forre O, Kåss E, Terenius L. Elevated CSF levels of substance P and high incidence of raynaud phenomenon in patients with fibromyalgia: New features for diagnosis. Pain 1988;32:21-26.
46. Rosén A, Franck J, Brodin E. Effects of acute systemic treatment with the 5 HT-uptake blocker alaproclate on tissue levels and release of substance P in rat periaqueductal grey. Neuropeptides 1995;28:317-324.